Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PREDICT‐1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events

29 May 2007

Abstract excerpt

Pharmacogenetics (PGx) - the study of DNA variation in the human genome and the way this impacts the efficacy and safety of medicines - is becoming an increasingly important research tool as physicians, patients, regulatory authorities and payers look for innovative ways to improve the risk:benefit ratio of medicines. While scientific knowledge about PGx is rapidly increasing, implementation of PGx findings to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug-Induced Adverse Reactions
Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17534855
DOI: 10.1002/pst.286

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PREDICT‐1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse eventsPMID 17534855Read ↗

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Semantic proximity Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

[Prospective validation of a pharmacogenetic test: the PREDICT-1 study].Semantic proximity Read ↗

Successful translation of pharmacogenetics into the clinic: the abacavir example.Semantic proximity Read ↗

HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.Semantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.Semantic proximity Read ↗

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.Semantic proximity Read ↗

Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescriptionSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utilitySemantic proximity Read ↗

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.